Standard

SARS-CoV-2 breakthrough infections in patients with immune-mediated inflammatory diseases during the omicron dominant period. / Boekel, Laura; Besten, Yaëlle R.; Hooijberg, Femke et al.

In: The Lancet Rheumatology, Vol. 4, No. 11, 01.11.2022, p. e747-e750.

Research output: Contribution to journal › Comment/Letter to the editor › Academic

Harvard

Boekel, L, Besten, YR, Hooijberg, F, Wartena, R, Steenhuis, M, Vogelzang, E, Leeuw, M, Atiqi, S, Tas, SW, Lems, WF, van Ham, SM, Eftimov, F, Stalman, EW, Wieske, L, Kuijpers, TW, Voskuyl, AE, van Vollenhoven, RF, Gerritsen, M, Krieckaert, C, Rispens, T, Boers, M, Nurmohamed, MT & Wolbink, G 2022, 'SARS-CoV-2 breakthrough infections in patients with immune-mediated inflammatory diseases during the omicron dominant period', The Lancet Rheumatology, vol. 4, no. 11, pp. e747-e750. https://doi.org/10.1016/S2665-9913(22)00221-1

APA

Boekel, L., Besten, Y. R., Hooijberg, F., Wartena, R., Steenhuis, M., Vogelzang, E., Leeuw, M., Atiqi, S., Tas, S. W., Lems, W. F., van Ham, S. M., Eftimov, F., Stalman, E. W., Wieske, L., Kuijpers, T. W., Voskuyl, A. E., van Vollenhoven, R. F., Gerritsen, M., Krieckaert, C., ... Wolbink, G. (2022). SARS-CoV-2 breakthrough infections in patients with immune-mediated inflammatory diseases during the omicron dominant period. The Lancet Rheumatology, 4(11), e747-e750. https://doi.org/10.1016/S2665-9913(22)00221-1

Vancouver

Boekel L, Besten YR, Hooijberg F, Wartena R, Steenhuis M, Vogelzang E et al. SARS-CoV-2 breakthrough infections in patients with immune-mediated inflammatory diseases during the omicron dominant period. The Lancet Rheumatology. 2022 Nov 1;4(11):e747-e750. doi: 10.1016/S2665-9913(22)00221-1

Author

Boekel, Laura ; Besten, Yaëlle R. ; Hooijberg, Femke et al. / SARS-CoV-2 breakthrough infections in patients with immune-mediated inflammatory diseases during the omicron dominant period. In: The Lancet Rheumatology. 2022 ; Vol. 4, No. 11. pp. e747-e750.

BibTeX

@article{71b76b2165bd49318bdf0ca187cd2772,
title = "SARS-CoV-2 breakthrough infections in patients with immune-mediated inflammatory diseases during the omicron dominant period",
author = "Laura Boekel and Besten, {Ya{\"e}lle R.} and Femke Hooijberg and Rosa Wartena and Maurice Steenhuis and Erik Vogelzang and Maureen Leeuw and Sadaf Atiqi and Tas, {Sander W.} and Lems, {Willem F.} and {van Ham}, {S. Marieke} and Filip Eftimov and Stalman, {Eileen W.} and Luuk Wieske and Kuijpers, {Taco W.} and Voskuyl, {Alexandre E.} and {van Vollenhoven}, {Ronald F.} and Martijn Gerritsen and Charlotte Krieckaert and Theo Rispens and Maarten Boers and Nurmohamed, {Mike T.} and Gertjan Wolbink",
note = "Funding Information: The study was supported by ZonMw and Reade Foundation. The funders had no role in study design, data analyses, or writing of the report. FE and TWK report (governmental) grants from ZonMw (the Netherlands Organization for Health Research and Development) to study immune responses after SARS-CoV-2 vaccination in autoimmune diseases. FE also reports grants from Prinses Beatrix Spierfonds, CSL Behring, Kedrion, Terumo BCT, Grifols, Takeda Pharmaceutical Company, and Guillain-Barr{\'e} Syndrome-Chronic Inflammatory Demyelinating Polyneuropathy (GBS-CIDP) Foundation; consulting fees from UCB Pharma and CSl Behring; and honoraria from Grifols. All other authors declare no competing interests. ",
year = "2022",
month = nov,
day = "1",
doi = "10.1016/S2665-9913(22)00221-1",
language = "English",
volume = "4",
pages = "e747--e750",
journal = "The Lancet Rheumatology",
issn = "2665-9913",
publisher = "Lancet Publishing Group",
number = "11",

}

RIS

TY - JOUR

T1 - SARS-CoV-2 breakthrough infections in patients with immune-mediated inflammatory diseases during the omicron dominant period

AU - Boekel, Laura

AU - Besten, Yaëlle R.

AU - Hooijberg, Femke

AU - Wartena, Rosa

AU - Steenhuis, Maurice

AU - Vogelzang, Erik

AU - Leeuw, Maureen

AU - Atiqi, Sadaf

AU - Tas, Sander W.

AU - Lems, Willem F.

AU - van Ham, S. Marieke

AU - Eftimov, Filip

AU - Stalman, Eileen W.

AU - Wieske, Luuk

AU - Kuijpers, Taco W.

AU - Voskuyl, Alexandre E.

AU - van Vollenhoven, Ronald F.

AU - Gerritsen, Martijn

AU - Krieckaert, Charlotte

AU - Rispens, Theo

AU - Boers, Maarten

AU - Nurmohamed, Mike T.

AU - Wolbink, Gertjan

N1 - Funding Information: The study was supported by ZonMw and Reade Foundation. The funders had no role in study design, data analyses, or writing of the report. FE and TWK report (governmental) grants from ZonMw (the Netherlands Organization for Health Research and Development) to study immune responses after SARS-CoV-2 vaccination in autoimmune diseases. FE also reports grants from Prinses Beatrix Spierfonds, CSL Behring, Kedrion, Terumo BCT, Grifols, Takeda Pharmaceutical Company, and Guillain-Barré Syndrome-Chronic Inflammatory Demyelinating Polyneuropathy (GBS-CIDP) Foundation; consulting fees from UCB Pharma and CSl Behring; and honoraria from Grifols. All other authors declare no competing interests.

PY - 2022/11/1

Y1 - 2022/11/1

UR - http://www.scopus.com/inward/record.url?scp=85140488530&partnerID=8YFLogxK

U2 - 10.1016/S2665-9913(22)00221-1

DO - 10.1016/S2665-9913(22)00221-1

M3 - Comment/Letter to the editor

C2 - 36034738

VL - 4

SP - e747-e750

JO - The Lancet Rheumatology

JF - The Lancet Rheumatology

SN - 2665-9913

IS - 11

ER -

ID: 26637398